Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (antiEGFR mAb) therapy, but many tumors containing wild-type RAS genes still do not respond to these therapies.